Navigation Links
YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB
Date:6/23/2009

ival (p = 0.0018) favoring nimotuzumab. The addition of nimotuzumab did not add to the toxicities of either regimen, with no Grade III/IV skin toxicities observed. The trial demonstrates that the efficacy of nimotuzumab compares favorably to results reported for cetuximab, an EGFR-targeting antibody marketed as Erbitux(R), but that this efficacy was not accompanied by the severe toxicities reported in patients treated with cetuximab.

YM BioSciences today posted a series of documents on its website, www.ymbiosciences.com that address frequently asked questions made by the investment community and pharmaceutical industry relating to YM's products and business strategy. A comprehensive description of the completed and ongoing trials being conducted by YM and the other licensees of nimotuzumab is also available at YM's website.

About YM BioSciences

YM BioSciences Inc. is a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development. The Company is currently developing two late-stage products: nimotuzumab, an EGFR-targeting Affinity-Optimized Antibody(TM), and AeroLEF(R), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization.

Nimotuzumab is a humanized monoclonal antibody in development worldwide, targeting multiple tumor types primarily in combination with radiation and chemoradiation. It is significantly differentiated from all other currently marketed EGFR-targeting agents due to its remarkably benign side-effect profile. Nimotuzumab's anti-tumor activity has led to its approval for marketing in more than 12 countries. In more
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 2015  Actavis plc (NYSE: ACT ) today ... Appeals for the Second Circuit has issued a ruling ... Company to continue distribution of NAMENDA ® (memantine ...   "While we are disappointed by ... to continue our strong efforts to convey the significant ...
(Date:5/22/2015)... NJ (PRWEB) May 22, 2015 ... new white paper that explores the potential of big ... The white paper was developed to help life sciences ... can leverage data to gain critical business insights. , ... large amounts of data driven by patient profiling, compliance ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 Seventh Wave ... safety and efficacy of pharmaceutical products and medical devices, ... Heights, MO 63043, a 50,000 sq. ft. building more ... to enable strategic growth. Facility renovations will begin immediately ... new space will occur in September. , “We ...
(Date:5/21/2015)... YORK , May 21, 2015  Prima Biomed ... company that is striving to become a leader in ... cancer, recently announced that the final CVac data from ... shown a clear trend for a clinically meaningful improvement ... in second remission patients. In the group ...
Breaking Biology Technology:Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 2Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 3Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 4Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 5Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 6Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 7Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 8New White Paper Explores the Potential of Big Data Analytics in Life Sciences and Healthcare 2Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 2Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 3Correction Continues after Big Move - BrokerBank Securities, Inc. 2
... MATEO, Calif., Feb. 4 NeurogesX, Inc. (Nasdaq: ... and commercializing novel pain management therapies, announced today that ... to present at the 11th Annual BIO CEO & ... 10, 2009. Mr. DiTonno and Stephen Ghiglieri, Chief Financial ...
... Genesis HealthCare, a provider of long-term care ... announced today that Wendy LaBate has been promoted to ... In her new position, LaBate will be responsible ... Genesis, Regional Vice Presidents of Operations and Administrators in ...
... Mich., Feb. 4 Diplomat Specialty Pharmacy is,pleased ... As of January 2009, DSP launched both ... Scott Reed has joined Diplomat as National,Sales Manager ... Indiana University and,has over 18 years ...
Cached Biology Technology:NeurogesX to Present at 11th Annual BIO CEO & Investor Conference 2NeurogesX to Present at 11th Annual BIO CEO & Investor Conference 3Genesis HealthCare Promotes Wendy LaBate To Senior Vice President of Operations for the Northeast Area 2Diplomat Specialty Pharmacy Expands National Hemophilia & IVIG Program 2
(Date:4/17/2015)... 2015 Increasing adoption ... advancement to drive biometric systems market in ... According to a recently released TechSci ... ", biometric systems market in Saudi ... at CAGR of over 22% through 2020. The ...
(Date:4/13/2015)... 2015 According to a ... Market Forecast & Opportunities, 2020", the global biometrics market ... 14% till 2020. The biometrics market is garnering ... and review of biometric management systems. The constant ... with greater efficiency, are resulting in increasing installation ...
(Date:4/9/2015)... , April 9, 2015 Synaptics Inc. (NASDAQ: ... solutions, announced today that it will report financial results ... April 23, 2015, after the close of market. The ... and investors at 2:00 p.m. PT (5:00 p.m. ET), ... To participate on the live call, analysts and ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2Synaptics to Report Third Quarter Results on April 23 2
... temperate forests across the United States, choking out native ... of Illinois ecologist Adam Davis has created a computer ... believes will be able to predict the perfect predator ... forested area that will help reduce the garlic mustard ...
... The Wildlife Conservation Society and the Panthera Foundation ... from Bhutan to Burma that would allow tiger populations ... at the United Nations on January 30th, would span ... habitat left on earth. , Dr. Alan Rabinowitz, ...
... A new thesis from he Swedish medical university Karolinska ... men and women. The scientists who conducted the study ... why depression and chronic anxiety are more common in ... brain neurotransmitter that is critical to the development and ...
Cached Biology News:Predicting the perfect predator 2Predicting the perfect predator 3'Genetic corridors' are next step to saving tigers 2'Genetic corridors' are next step to saving tigers 3
The Protein Kinase Factsbooks (2 Volume Set)...
... PhastGel DNA Silver Staining Kit, 1. ... gels.Separate proteins and peptides on denaturing, ... and improve reproducibility with precast gels, ... sensitivity comparable to that of radioisotopes ...
ANTI S. ENT TOX BC2D...
Porcine Serum US Origin 6 Months or Older...
Biology Products: